Table 1.

Subject demographic and clinical characteristics

Group	No. of women	Age (y)	Headache days/3 mo	Disability		Medication use last 3 mo
				MIDAS	HIT-6	NSAID	Actmnphn	Excedrin	Triptan	Preventive
Controls	13/20	31 (5)	1.3 (1.4)	0.5 (0.8)	40.7 (4.1)	14	1	0	0	0
MwA	19/20	31 (4)	13.1 (8.9)	18.6 (15.3)	60.6 (8.0)	16	5	6	5	1
MwoA	17/20	30 (4)	11.7 (9.7)	16.0 (13.7)	60.0 (8.8)	17	2	1	1	3

Participants were asked to report the number of headaches they had experienced over the prior 3 mo. The MIDAS (28) and the HIT-6 (29) measure headache disability. Where appropriate, the mean value (and SD) across subjects is reported. Medication use is summarized within five categories: actmnphn, acetaminophen for any indication; Excedrin, use of any one of multiple formulations that combine an NSAID with acetaminophen to treat headache; NSAID, NSAID for any indication; preventive, any one of several classes of medications used to decrease migraine frequency (e.g., tricyclic antidepressants, beta-blockers); triptan, any tryptamine-based drug used to abort a migraine.